PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.27%
Revenue growth above 1.5x MRVL's 4.29%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
7.27%
Gross profit growth above 1.5x MRVL's 3.82%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-368.46%
Negative EBIT growth while MRVL is at 8.09%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-368.46%
Negative operating income growth while MRVL is at 15.99%. Joel Greenblatt would press for urgent turnaround measures.
1.71%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.11%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
1.11%
Diluted share count expanding well above MRVL's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.19%
10Y revenue/share CAGR at 50-75% of MRVL's 56.20%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
31.19%
5Y revenue/share CAGR under 50% of MRVL's 109.65%. Michael Burry would suspect a significant competitive gap or product weakness.
31.19%
3Y revenue/share CAGR 1.25-1.5x MRVL's 25.49%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
317.31%
Below 50% of MRVL's 653.69%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
317.31%
5Y net income/share CAGR 1.25-1.5x MRVL's 220.76%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
317.31%
3Y net income/share CAGR above 1.5x MRVL's 202.86%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
13.09%
Below 50% of MRVL's 54.87%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
13.09%
5Y equity/share CAGR at 50-75% of MRVL's 19.67%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
13.09%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
-46.00%
Cut dividends over 10 years while MRVL stands at 0.04%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-46.00%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-46.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.